European Case Law Identifier: | ECLI:EP:BA:2003:T030899.20030602 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 02 June 2003 | ||||||||
Case number: | T 0308/99 | ||||||||
Application number: | 86306046.3 | ||||||||
IPC class: | A61K 47/36 | ||||||||
Language of proceedings: | EN | ||||||||
Distribution: | C | ||||||||
Download and more information: |
|
||||||||
Title of application: | Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same | ||||||||
Applicant name: | Biomatrix, Inc. | ||||||||
Opponent name: | Biomatrix Inc. FIDIA, S.p.A. |
||||||||
Board: | 3.3.02 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: | |||||||||
Keywords: | Novelty (yes): claimed use reflects a newly discovered technical effect Inventive step (no): claimed use is based on a thoroughly obvious property of known substances; slightly enhanced effects associated with the claimed use in comparision with substances used in the state of the art emerge from obvious tests - no indication of an inventive step |
||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t990308eu1.html
Date retrieved: 17 May 2021